Drug Profile
Research programme: histone deacetylase inhibitors - FORUM Pharmaceuticals
Alternative Names: EVX 001688; HDAC inhibitors - EnVivo; HDACi - EnVivo; Isotope-selective HDAC inhibitors (Series B) - EnVivoLatest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator MethylGene
- Developer CHDI; Mirati Therapeutics
- Class Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Huntington's disease; Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)